Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States

Journal of Medical Economics

Volumn 14, Issue 2, 2011, Pages 167-178

  Broder, Michael S ^a   Chang, Eunice Y ^a   Bentley, Tanya G K ^a   Juday, Timothy ^b   Uy, Jonathan ^b  

^a PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral therapy; Cost effectiveness; HIV; Protease inhibitor

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; CHOLESTEROL; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFECT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFECTION RATE; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; MORTALITY; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT DURATION; UNITED STATES;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MARKOV CHAINS; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PYRIDINES; PYRIMIDINONES; QUALITY-ADJUSTED LIFE YEARS; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; RITONAVIR; UNITED STATES;

EID: 79952997587     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2011.554932     Document Type: Article

References (39)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelinesforthe use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009;1-146. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 14 April 2010]
2. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-59 (Pubitemid 351920404)
3. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of boosted once-daily atazanavir and twice-daily lopinavir regimens in treatment näveHIV-1 infected subjects. CASTLE: 48-week results. Presentedatthe15th Conference on Retroviruses and Opportunistic Infections (poster #37), Boston, 2008. Available at http://img.thebody.com/confs/retro2008/ slides/37%20 Molina%20CASTLE%20Presentation.pdf. [Last accessed 2 December 2009]
4. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with teno-fovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655
5. Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study. J Acquir Immune Defic Syndr 2010;53:323-332
6. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-168 (Pubitemid 27086806)
7. Worm SW, De Wit S, Weber R, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation 2009;119:805-811
8. American Heart Association. Heart Disease and Stroke Statistics-2009 Update. Dallas, Texas: American Heart Association; 2009
9. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/rito-navir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004;5:294-304 (Pubitemid 39545402)
10. Golin CE, Liu H, Hays RD, et al. Aprospectivestudyof predictorsofadherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-765 (Pubitemid 35286241)
11. National Vital Statistics Report Volume 56, Number 10. Deaths: Final data for 2005. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-10.pdf. [Last accessed 8 December 2009]
12. Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007;23:1505-1514
13. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30 (Pubitemid 30432540)
14. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183 (Pubitemid 32549871)
15. Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: the D:A:D CHD Risk Equation. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California
16. Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs forthe primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336 (Pubitemid 46768187)
17. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syn-drome on health-related quality of life. Gastroenterology 2000;119:654-660
18. Whitehead WE, Burnett CK, Cook 3rd EW, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996;41:2248-2253 (Pubitemid 26414448)
19. Creed F, Ratcliffe J, Fernandez L, et al. Health-related qualityof life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001;134:860-868 (Pubitemid 32405694)
20. Ingenix National Fee Analyzer 2008
21. Price Rx Wolters Kluwer Health 2009
22. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718 (Pubitemid 43884298)
23. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts. Infection 2009;37:244-249
24. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006;44:990-997 (Pubitemid 44674030)
25. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. New York, NY: Oxford University Press, 2005
26. Dale W, Basu A, Elstein A, et al. Predicting utility ratingsforjointhealthstates from single health states in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making 2008;28:102-112
27. Fu AZ, Kattan MW. Utilities should not be multiplied: evidence from prefer-ence-based scores in the United States. Med Care 2008;46:984-990
28. Bureau of Labor Statistics, U.S. Department of Labor. CPI Detailed Report: Datafor May 2009. Crawford M, Katz S, eds. www.bls.gov/cpi/cpid0905.pdf. Accessed June 30, 2009
29. Ubel PA, Hirth RA, Chernew ME,et al. What is the price of life and why doesn't it increase atthe rate of inflation? Arch Intern Med 2003;163:1637-1641 (Pubitemid 36898950)
30. King JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005;25:667-677 (Pubitemid 41667135)
31. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-528 (Pubitemid 39390832)
32. Grosse SD, Teutsch SM, Haddix AC Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health 2007;28:365-391 (Pubitemid 46833348)
33. King Jr JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005;25:667-677 (Pubitemid 41667135)
34. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase atthe rate of inflation? Arch Intern Med 2003;163:1637-1641 (Pubitemid 36898950)
35. Weinstein MC, Skinner JA. Comparative effectiveness and health care spend-ing-implicationsfor reform. N Engl J Med 2010;362:460-5. Epub 2010 Jan 6
36. Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir + ritonavir regimens in the CASTLE study. Adv Ther 2009;26:185-193
37. Simpson KN, Luo MP, Chumney EC, et al. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: model-ling the combined effects of HIV and heart disease. Clin Drug Invest 2007; 27:67-74 (Pubitemid 46058735)
38. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003;17:1741-1751 (Pubitemid 37000092)
39. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-694 (Pubitemid 40593073)